logo-loader
RNS
TheraCryf PLC

Posting of Annual Report and Notice of AGM

RNS Number : 8054W
Theracryf PLC
30 September 2026
 

A black background with blue letters

Description automatically generated

 

 

30 September 2026

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Posting of Annual Report and Notice of AGM

 

TheraCryf plc, the biotech company developing new medicines for addiction and other neuropsychiatric disorders, announces that its Annual Report and Accounts for the year ended 31 March 2026 and Notice of the Annual General Meeting have been posted to shareholders and are now available on the Company website at https://theracryf.com/investors/.

 

The Company's Annual General Meeting will take place at 2.00 pm on Thursday, 22 October 2026 at Smithfield Offices, 5 St John’s Lane, London, EC1M 4BH.

 

 

-Ends-

Enquiries

 

TheraCryf plc

Dr Huw Jones, CEO

Toni Hänninen, CFO

Dr Helen Kuhlman, COO

 

+44 (0)1625 315 090

enquiries@theracryf.com

Singer Capital Markets (NOMAD & Joint Broker)
Russell Cook / Alex Bond

 

+44 (0)20 7496 3000

Turner Pope Investments (Joint Broker)

Guy McDougall / Andy Thacker 

 

+44 (0)20 3657 0050

 

Northstar Communications (Investor Relations)

Sarah Hollins

+44 (0)113 730 3896

sarah@northstarcommunications.co.uk

 

 

About TheraCryf

 

TheraCryf plc is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of significant unmet medical need.

 

The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders.

The programme has already been heavily de-risked for both safety/tolerability and efficacy in previous testing and is fully funded through final pre-clinical trials to clinical readiness, with regulatory submissions for first in man studies targeted for 2026.

 

TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.

 

The Group operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with commercially focused pharmaceutical and biotechnology companies.

 

TheraCryf’s headquarters and registered office are at Alderley Park, Cheshire.

 

For further information, visit: https://theracryf.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAFKLFLQKLLBBE
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read